The ERISA Industry Committee Supports IRS Rule Permitting Workers and Spouses to Execute Retirement Plan Decisions Using Video Conferencing Technology

WASHINGTON, March 30, 2023 – The ERISA Industry Committee (ERIC) today submitted comments supporting an Internal Revenue Service (IRS) proposed regulation permanently allowing notary publics, pension plan representatives, and plan participants and their spouses to use secure video conferencing technology to officially execute certain decisions about retirement benefits.

Employers Urge the U.S. Senate Finance Committee to Reform the Pharmacy Benefit Manager Business Model

Washington, D.C., March 30, 2023 – Employers’ Prescription for Affordable Drugs (EmployersRx), of which The ERISA Industry Committee (ERIC) is a member, provided a statement for the U.S. Senate Finance Full Committee’s hearing on “Pharmacy Benefit Managers (PBM) and the Prescription Drug Supply Chain: Impact on Patients and Taxpayers” highlighting the need for federal action to better understand PBM practices.

The ERISA Industry Committee Backs the Reintroduction of the Telehealth Expansion Act

WASHINGTON, March 29, 2023 – Yesterday, The ERISA Industry Committee (ERIC) sent letters of support to House and Senate leaders who reintroduced the Telehealth Expansion Act, bipartisan, bicameral legislation making permanent first-dollar coverage of telehealth services for employees enrolled in a high deductible health plan (HDHP) coupled with a health savings account (HSA).

The ERISA Industry Committee Files Reply Brief in Ongoing NJ WARN Act Lawsuit

Washington, D.C., March 28, 2023 – The ERISA Industry Committee (ERIC) today filed a reply brief in its ongoing lawsuit to defeat the amended New Jersey WARN Act on ERISA preemption grounds. This submission concludes the district court briefing process, leaving just under two weeks for a decision to be reached before the amended law’s April 10 effective date.

The ERISA Industry Committee Endorses the Chronic Disease Management Act of 2023

WASHINGTON, DC, March 27, 2023 – In a letter sent today to Senators Tom Carper (D-DE) and John Thune (R-SD), The ERISA Industry Committee (ERIC) applauded the introduction of legislation that will allow employers to cover a limited but critical set of medical needs related to chronic disease management prior to the patient reaching his or her plan deductible.  

ERIC Supports Senate Legislation to Hold Hospitals Accountable to Price Transparency Regulations

WASHINGTON, DC, March 24, 2023 – The ERISA Industry Committee (ERIC) issued a letter of support today for the Hospital Transparency Compliance Enforcement Act (S. 468), legislation introduced by Senator John Kennedy (R-LA) that would impose higher fines for hospitals that do not make publicly available the cost of contracted health care services with insurers – holding hospitals accountable to the 2021 Price Transparency Regulations.

The “Pharmacy Benefit Manager Transparency Act” Does Too Little to Bring Transparency and Accountability to the Prescription Drug Market

WASHINGTON, DC, March 22, 2023 – In a letter sent yesterday to the U.S. Senate Committee on Commerce, Science, and Transportation, The ERISA Industry Committee (ERIC) urged the members to vote no on the Pharmacy Benefit Manager Transparency Act (PBMTA, S. 127), legislation that fails to include employer-focused, comprehensive solutions that would bring clarity and responsibility to the prescription drug supply chain.

The ERISA Industry Committee Refiles Motion for Summary Judgment in NJ WARN Act Lawsuit

Washington, D.C., March 14, 2023 – The ERISA Industry Committee (ERIC) today refiled a motion for summary judgment in its ongoing lawsuit, The ERISA Industry Committee v. Robert Asaro-Angelo, the Commissioner of the New Jersey Department of Labor and Workforce Development. This filing follows the completion of an expedited discovery process ordered by the Court, regarding ERIC’s standing to file the suit.